Novavax shares fell 11.2% during Wednesday's session. Vaccine stocks are volatile after the first US bird flu death and a CDC report on rising respiratory illnesses. Brand New Membership Level ...

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

In the most recent trading session, Novavax (NVAX) closed at $8.45, indicating a +0.24% shift from the previous trading day. Health and pharmaceutical stocks — including Moderna (MRNA), Pfizer ...

Novavax shares are trading lower by 9.8% during Monday's session. Shares of vaccine stocks are trading lower after Moderna issued 2025 revenue guidance below analyst estimates. Next: Access Our ...

Novavax (NVAX) ended the recent trading session at $8.55, demonstrating a +0.53% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily gain of 1.83% ...

Appearances by CFO Kelly and R&D Head Draghia at the 11/2024 London Jeffries Healthcare conference provide the latest insights for Novavax's future priorities. In Kelly's opening discussion he ...

He added that if there were ever a discussion in the future of a sale or acquisition, the board "would always consider appropriately for our shareholders the right path to value." Novavax beat on ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and ...

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...